Jim Barrett is a business lawyer who represents life sciences and healthcare companies as well as venture capital and private equity funds in US and cross-border transactions. He regularly counsels boards of directors and general partners on transactions and corporate governance matters and guides their businesses through all stages of development. Accordingly, Jim concentrates on private equity and venture capital investment transactions, mergers and acquisitions, and general corporate representation.
Jim recently served as co-chair of Goodwin’s Pro Bono Committee.
Experience
Jim’s representative clients include the following:
- Albert Einstein College of Medicine of Yeshiva University
- Aperture Therapeutics
- Ampersand Capital Partners
- Arranta Bio
- Beacon Intelligence
- BioInnovation Capital
- BioLabs
- Brammer Bio, LLC
- Confluent Medical Technologies, Inc.
- Conifer
- Conigen
- Cormorant Asset Management
- Flagship Biosciences
- Genezen
- Gannet
- iCarbonX Group Limited
- Lab Central Inc.
- Landmark Bio
- MainStPBC
- Medpharm
- Mission BioCapital
- MPM Capital
- Nuvinka
- Nano Terra
- Cormornat
- PatientsLikeMe
- Phosphorex
- Protagene GmbH
- PureTech Health plc
- Recipharm AB
- Resolian
- RhoBio
- Script Bio AI
- Seaport Therapeutics
- StageBio
- Vantage
- VIVEbiotech
Professional Experience
Prior to joining Goodwin in 2015, Jim was a partner at Locke Lord in Boston, where he served as co-chair of its private equity/venture capital group.
Credentials
Education
JD
University of Pennsylvania Law School
BA
University of Pennsylvania
Admissions
Bars
- Massachusetts
Recognition & Awards
Jim has been recognized by The Best Lawyers in America Best Lawyers for his work in Corporate Law 2022-2023 and 2027.